Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib
- Sponsor
- Alfredo Berruti
- Study ID
- NCT05265988
- Phase
- PHASE2
- Status
- Completed
Conditions
- Carcinoma Prostate
Eligibility Criteria
- Sex
- MALE
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Interventions
- Cabozantinib — DRUGCabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
Study Details
Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study
Key Dates
- Start date
- Nov 29, 2021
- Status verified
- Jul 2024
- Primary completion
- Jun 29, 2024
- Completion
- Jun 29, 2024
Study Design
- Enrollment
- 32 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: MeridianCabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
Primary Outcome Measure
Objective response rate (ORR) on bone metastases through whole body diffusione weighted (WB-DW) MRI. [ Time Frame: 6 months ]